Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mexico-US Genomics Partnership Launches Second Phase

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
SIGMA 2 is aimed at harnessing genomic medicine for the benefit of Latin America and the world.

SIGMA is an unprecedented partnership that aims to ensure that Latin Americans benefit from the genomic revolution by:

•    Promoting wider access to genomic medicine in Mexico and Latin America by supporting discovery programs that focus on health problems with particular relevance to the region, and leverage its unique population genetics, and
•    Enhancing genomic research capacity in Mexico through training of scientists and encouraging the development of genomic diagnostics and therapeutics in Latin America.

The partnership brings together three organizations — the Broad Institute, the Carlos Slim Health Institute, and the National Institute of Genomic Medicine of Mexico — with a shared commitment to transforming human health. The work will be carried out in coordination with scientists from Mexican institutions, like the National Autonomous University and the National Institute of Medical Sciences and Nutrition, led by the Carlos Slim Center for Health Research at the Broad Institute.

Carlos Slim Hélu, together with Broad Institute President and Director Eric Lander, announced SIGMA 2 during a special event on Monday at the Broad Institute.

“Most genomic research has focused on European or European-derived populations. It’s like doing science with one eye closed. There are many discoveries that can only be made by studying non-European populations,” said Dr. Lander. “In addition to the scientific importance of studies in Latin America, it is essential that the benefits of the genomic revolution be accessible to people throughout the Americas and the world.”

“I am incredibly grateful to Carlos Slim for his extraordinary commitment to improving public health,” added Dr. Lander.

SIGMA 2 aims to develop new biomedical approaches to some of the most crucial problems in public health, including cancer, type 2 diabetes, and kidney disease. It builds upon an initial effort launched in 2010 with the Carlos Slim Health Institute.

“The Broad Institute is a world leader in genomic medicine and shares our own vision for overcoming some of the greatest challenges and solutions in public health,” said Carlos Slim Hélu. “I am convinced that the discoveries we make together will strongly impact the population in Mexico and worldwide.”

With an initial donation of $65M by the Carlos Slim Foundation, in the first phase of SIGMA Broad scientists worked closely with Mexican colleagues and with researchers from across the Broad’s partner institutions to systematically identify genes underlying cancer, diabetes and kidney disease. The project yielded deep biomedical insights in each of its three core areas. These include:

•    In type 2 diabetes, scientists identified a common genetic variant predisposing Latin American populations to the disease. Because this genetic variant is absent in Europeans, it had been previously overlooked.
•    In cancer, researchers identified new genetic drivers of breast cancer, lymphoma, head and neck cancer, and other cancers.
•    In kidney disease, the Mexico-US team discovered the gene for medullary cystic kidney disease type 1 (MCKD1) — a rare disorder that ultimately requires dialysis or kidney transplantation.

The SIGMA 2 project, while continuing its early discovery efforts, will focus on translating these discoveries into clinical impact, including the development of diagnostic tools for breast cancer and diabetes, completing the genetic analysis of these diseases, creating therapeutic “roadmaps” to guide the development of new treatments, and the launching of a full-scale effort to target MCKD1.

In addition, SIGMA 2 will continue to work on building scientific capacity in the US and Mexico. In the initial phase, the project engaged scientists across 125 institutions in both countries. Going forward, the project will aim to substantially increase its collaborative scope.

“In just a few years, our work together with our colleagues in Mexico has been enormously productive and enriching to the scientific community,” said Dr. Lander. “It’s now time to expand this international partnership so that it truly benefits our children — both in Mexico and in the United States.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Broad Institute & Google Genomics Combine Bioinformatics and Computing Expertise
Both companies explore how to break down major technical barriers that increasingly hinder biomedical research.
Thursday, June 25, 2015
CRISP-Disp Leverages CRISPR-Cas9 to Deliver RNA Structures to Targets in the Genome
A team of researchers from the Broad Institute and the Harvard Stem Cell Institute has developed CRISP-Disp, a method that expands on the CRISPR-Cas9 system, allowing researchers to display multiple, large RNA structures on the Cas9 protein.
Wednesday, June 10, 2015
GTEx: Useful Expression For Cancer Research
GTEx Project has recently published several papers reporting on findings from its two-year pilot phase.
Tuesday, May 26, 2015
Single-cell Analysis Hits its Stride
Advances in technology and computational analysis enable scale and affordability, paving the way for translational studies.
Saturday, May 23, 2015
Highly Efficient New Cas9 for In Vivo Genome Editing
New finding is expected to expand therapeutic and experimental applications of CRISPR.
Tuesday, April 07, 2015
Broad Institute of MIT and Harvard and Bayer Healthcare Expand their Partnership
Collaboration to develop therapies for cardiovascular disease.
Thursday, April 02, 2015
In vivo CRISPR-Cas9 Screen Sheds Light On Cancer Metastasis And Tumor Evolution
Genome-scale study points to drivers of tumor evolution and metastasis, provides roadmap for future in vivo Cas9 screens.
Friday, March 06, 2015
Scientists Map the Human Loop-ome, Revealing a New Form of Genetic Regulation
Researchers describe the results of a five-year effort to map, in unprecedented detail, how the 2-meter long human genome folds inside the nucleus of a cell.
Tuesday, December 23, 2014
Disorder in Gene-Control System is a Defining Characteristic of Cancer, Study Finds
Findings indicate that the disarray in the on-off mechanism is one of the defining characteristics of cancer.
Tuesday, December 23, 2014
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Friday, October 10, 2014
Study Expands the Cancer Genomics Universe
The universe of cancer mutations is much bigger than previously thought, and key cancer genes are still to be discovered.
Tuesday, January 28, 2014
Predicting Cancer’s Next Move
Research offers a new approach to studying drug resistance in cancer.
Monday, November 11, 2013
Understanding Triglycerides’ Role in Coronary Disease
The study leverages new genetic data from a related genome-wide association study, suggests that lowering triglyceride levels through treatment may help reduce the risk of coronary heart disease.
Wednesday, October 09, 2013
Study Finds Rules for Cancer Drivers
Any number of alterations to an individual’s genetic code has the potential to make a cell malfunction and proliferate into cancer tumors.
Monday, September 30, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!